Madrigal Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $174.86
- Today's High:
- $186.69
- Open Price:
- $184.82
- 52W Low:
- $57.21
- 52W High:
- $322.67
- Prev. Close:
- $184.99
- Volume:
- 433217
Company Statistics
- Market Cap.:
- $3.42 billion
- Book Value:
- 5.607
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -79.62%
- Return on Equity TTM:
- -352.65%
Company Profile
Madrigal Pharmaceuticals Inc had its IPO on 2007-02-06 under the ticker symbol MDGL.
The company operates in the Healthcare sector and Biotechnology industry. Madrigal Pharmaceuticals Inc has a staff strength of 92 employees.
Stock update
Shares of Madrigal Pharmaceuticals Inc opened at $184.82 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $174.86 - $186.69, and closed at $176.87.
This is a -4.39% slip from the previous day's closing price.
A total volume of 433,217 shares were traded at the close of the day’s session.
In the last one week, shares of Madrigal Pharmaceuticals Inc have slipped by -4.47%.
Madrigal Pharmaceuticals Inc's Key Ratios
Madrigal Pharmaceuticals Inc has a market cap of $3.42 billion, indicating a price to book ratio of 93.5958 and a price to sales ratio of 0.
In the last 12-months Madrigal Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-329996992. The EBITDA ratio measures Madrigal Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Madrigal Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -79.62% with a return of equity of -352.65%.
In Q2, Madrigal Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Madrigal Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-19.19 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Madrigal Pharmaceuticals Inc’s profitability.
Madrigal Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.2927. Its price to sales ratio in the trailing 12-months stood at 0.
Madrigal Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $302.46 million
- Total Liabilities
- $99.71 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $69000
- Dividend Payout Ratio
- 0%
Madrigal Pharmaceuticals Inc ended 2024 with $302.46 million in total assets and $0 in total liabilities. Its intangible assets were valued at $302.46 million while shareholder equity stood at $103.51 million.
Madrigal Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $99.71 million in other current liabilities, 2000.00 in common stock, $-1125356000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $77.20 million and cash and short-term investments were $298.42 million. The company’s total short-term debt was $411,000 while long-term debt stood at $99.25 million.
Madrigal Pharmaceuticals Inc’s total current assets stands at $301.60 million while long-term investments were $0 and short-term investments were $221.22 million. Its net receivables were $0 compared to accounts payable of $17.53 million and inventory worth $0.
In 2024, Madrigal Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $69000.
Comparatively, Madrigal Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $176.87
- 52-Week High
- $322.67
- 52-Week Low
- $57.21
- Analyst Target Price
- $331.17
Madrigal Pharmaceuticals Inc stock is currently trading at $176.87 per share. It touched a 52-week high of $322.67 and a 52-week low of $322.67. Analysts tracking the stock have a 12-month average target price of $331.17.
Its 50-day moving average was $195.2 and 200-day moving average was $235.2 The short ratio stood at 6.42 indicating a short percent outstanding of 0%.
Around 989.5% of the company’s stock are held by insiders while 8506.6% are held by institutions.
Frequently Asked Questions About Madrigal Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.